<SEC-DOCUMENT>0001104659-25-085522.txt : 20250829
<SEC-HEADER>0001104659-25-085522.hdr.sgml : 20250829
<ACCEPTANCE-DATETIME>20250829135850
ACCESSION NUMBER:		0001104659-25-085522
CONFORMED SUBMISSION TYPE:	N-PX
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250829
DATE AS OF CHANGE:		20250829
EFFECTIVENESS DATE:		20250829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			abrdn Life Sciences Investors
		CENTRAL INDEX KEY:			0000884121
		ORGANIZATION NAME:           	
		EIN:				043147016
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		N-PX
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-06565
		FILM NUMBER:		251279626

	BUSINESS ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		6177728515

	MAIL ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKLA LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	20141015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	H&Q LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	19920929
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-PX
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/npx" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>N-PX</submissionType>
    <filerInfo>
      <registrantType>RMIC</registrantType>
      <liveTestFlag>LIVE</liveTestFlag>
      <filer>
        <issuerCredentials>
          <cik>0000884121</cik>
          <ccc>XXXXXXXX</ccc>
          <!--Field: Pseudo-Tag; ID: Name; Data:-->
        </issuerCredentials>
      </filer>
      <flags>
        <overrideInternetFlag>false</overrideInternetFlag>
        <confirmingCopyFlag>false</confirmingCopyFlag>
      </flags>
      <investmentCompanyType>N-2</investmentCompanyType>
      <periodOfReport>06/30/2025</periodOfReport>
    </filerInfo>
  </headerData>
  <formData>
    <coverPage>
      <yearOrQuarter>YEAR</yearOrQuarter>
      <reportCalendarYear>2025</reportCalendarYear>
      <reportingPerson>
        <name>abrdn Life Sciences Investors</name>
        <phoneNumber>800-522-5465</phoneNumber>
        <address>
          <com:street1>1900 Market St., Suite 200</com:street1>
          <com:city>Philadelphia</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>19103</com:zipCode>
        </address>
      </reportingPerson>
      <agentForService>
        <name>Lucia Sitar, Esq.</name>
        <address>
          <com:street1>1900 Market St., Suite 200</com:street1>
          <com:city>Philadelphia</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>19103</com:zipCode>
        </address>
      </agentForService>
      <reportInfo>
        <reportType>FUND VOTING REPORT</reportType>
      </reportInfo>
      <fileNumber>811-06565</fileNumber>
      <leiNumber>5493007BYZPSOVVS0M04</leiNumber>
      <explanatoryInformation>
        <explanatoryChoice>N</explanatoryChoice>
      </explanatoryInformation>
    </coverPage>
    <summaryPage>
      <otherIncludedManagersCount>0</otherIncludedManagersCount>
    </summaryPage>
    <seriesPage>
      <seriesCount>0</seriesCount>
    </seriesPage>
    <signaturePage>
      <reportingPerson>abrdn Life Sciences Investors</reportingPerson>
      <txSignature>Alan Goodson</txSignature>
      <txPrintedSignature>Alan Goodson</txPrintedSignature>
      <txTitle>President (Principal Executive Officer)</txTitle>
      <txAsOfDate>08/29/2025</txAsOfDate>
    </signaturePage>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>PROXY VOTING RECORD
<SEQUENCE>2
<FILENAME>proxytable.xml
<TEXT>
<XML>
<?xml version="1.0" ?>
<proxyVoteTable xmlns="http://www.sec.gov/edgar/document/npxproxy/informationtable">
  <proxyTable>
    <issuerName>Priothera Limited</issuerName>
    <meetingDate>07/09/2024</meetingDate>
    <voteDescription>Approve Dec 31 2022 financial statements</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>152534.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>152534.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Priothera Limited</issuerName>
    <meetingDate>07/09/2024</meetingDate>
    <voteDescription>Re-appoint statutory auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>152534.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>152534.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Priothera Limited</issuerName>
    <meetingDate>07/09/2024</meetingDate>
    <voteDescription>Authorize directors to approve remuneration of the statutory auditors for the calendar year 2023</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>152534.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>152534.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Laura J. Hamill</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Patrick Kennedy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Kenneth W. O'Keefe</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Mark D. Smith, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers, as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Jazz Pharmaceuticals plc</issuerName>
    <cusip>G50871105</cusip>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>07/25/2024</meetingDate>
    <voteDescription>To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 5.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>13116.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>13116.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunovant, Inc.</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/12/2024</meetingDate>
    <voteDescription>To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Peter Salzmann, M.D., M.B.A.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>137109.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>137109.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunovant, Inc.</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/12/2024</meetingDate>
    <voteDescription>To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: George Migausky</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>137109.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>137109.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunovant, Inc.</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/12/2024</meetingDate>
    <voteDescription>To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>137109.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>137109.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunovant, Inc.</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/12/2024</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>137109.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>137109.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunovant, Inc.</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/12/2024</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>137109.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>137109.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To approve (i) the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to the accompanying proxy statement/prospectus, and (ii) the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To approve an amendment to the amended and restated certificate of incorporation of ARCA (the &quot;ARCA Charter&quot;) to increase the number of shares of ARCA common stock that ARCA is authorized from 100,000,000 to issue to 545,000,000, in the form attached as Annex G to the accompanying proxy statement/prospectus;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA's issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as Annex H to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA's board of directors and Oruka's board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA's board of directors;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as Annex I to the accompanying proxy statement/prospectus;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To elect the Class III director, Jacob Ma-Weaver, to ARCA's board of directors and to hold office until ARCA's 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, provided that if the Merger is consummated, the approval of Proposal No. 5 will only have an effect until the completion of the Merger because the composition of ARCA's board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To ratify the appointment of KPMG LLP as ARCA's independent registered public accounting firm for fiscal year ending December 31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>08/22/2024</meetingDate>
    <voteDescription>To approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Roivant Sciences Ltd.</issuerName>
    <cusip>G76279101</cusip>
    <isin>BMG762791017</isin>
    <meetingDate>09/10/2024</meetingDate>
    <voteDescription>To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: Ilan Oren</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>379710.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>379710.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Roivant Sciences Ltd.</issuerName>
    <cusip>G76279101</cusip>
    <isin>BMG762791017</isin>
    <meetingDate>09/10/2024</meetingDate>
    <voteDescription>To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: James C. Momtazee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>379710.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>379710.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Roivant Sciences Ltd.</issuerName>
    <cusip>G76279101</cusip>
    <isin>BMG762791017</isin>
    <meetingDate>09/10/2024</meetingDate>
    <voteDescription>To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: Mayukh Sukhatme</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>379710.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>379710.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Roivant Sciences Ltd.</issuerName>
    <cusip>G76279101</cusip>
    <isin>BMG762791017</isin>
    <meetingDate>09/10/2024</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2025, to appoint Ernst &amp; Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2025, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst &amp; Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>379710.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>379710.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Roivant Sciences Ltd.</issuerName>
    <cusip>G76279101</cusip>
    <isin>BMG762791017</isin>
    <meetingDate>09/10/2024</meetingDate>
    <voteDescription>To cast a non-binding, advisory vote to approve the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>379710.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>379710.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Roivant Sciences Ltd.</issuerName>
    <cusip>G76279101</cusip>
    <isin>BMG762791017</isin>
    <meetingDate>09/10/2024</meetingDate>
    <voteDescription>To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers every:</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>379710.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>379710.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>09/18/2024</meetingDate>
    <voteDescription>Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Stuart A. Arbuckle</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38129.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>38129.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>09/18/2024</meetingDate>
    <voteDescription>Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Christophe R. Jean</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38129.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>38129.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>09/18/2024</meetingDate>
    <voteDescription>Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Lynn A. Tetrault</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38129.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>38129.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>09/18/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38129.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38129.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>09/18/2024</meetingDate>
    <voteDescription>Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38129.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38129.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>09/18/2024</meetingDate>
    <voteDescription>Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38129.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>38129.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>10/10/2024</meetingDate>
    <voteDescription>Elect Shawn Leland to Management Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>10/10/2024</meetingDate>
    <voteDescription>Approve Addendum to the Remuneration Policy for the Management Board in Respect of Shawn Leland</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Galera Therapeutics, Inc.</issuerName>
    <cusip>36338D108</cusip>
    <isin>US36338D1081</isin>
    <meetingDate>10/17/2024</meetingDate>
    <voteDescription>To approve the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the &quot;Plan of Dissolution&quot;) which, if approved, will authorize the Company's Board of Directors to liquidate and dissolve the Company in accordance with the Plan of Dissolution (the &quot;Dissolution Proposal&quot;).</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>125773.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Galera Therapeutics, Inc.</issuerName>
    <cusip>36338D108</cusip>
    <isin>US36338D1081</isin>
    <meetingDate>10/17/2024</meetingDate>
    <voteDescription>To adjourn the Special Meeting, from time to time, to a later date or dates, even if a quorum is present, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve the Dissolution Proposal.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>125773.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>10/23/2024</meetingDate>
    <voteDescription>Approval of an increase in the number of shares of our common stock available for issuance under our 2021 Equity and Incentive Plan by 5,500,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>226657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>226657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>10/23/2024</meetingDate>
    <voteDescription>Approval of the adjournment of the special meeting, if necessary, in the reasonable discretion of the Chairperson of the Board, to solicit additional proxies if there are insufficient votes at the time of the special meeting to approve the plan amendment.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>226657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>226657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oruka Therapeutics, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>11/14/2024</meetingDate>
    <voteDescription>To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company's common stock upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share, issued in September 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2705.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2705.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oruka Therapeutics, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>11/14/2024</meetingDate>
    <voteDescription>To approve an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2705.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2705.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>State Street Institutional Investment Trust</issuerName>
    <cusip>857492706</cusip>
    <isin>US8574927062</isin>
    <meetingDate>12/06/2024</meetingDate>
    <voteDescription>To Elect a Board of Trustees: Patrick J. Riley</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14893374.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14893374.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>State Street Institutional Investment Trust</issuerName>
    <cusip>857492706</cusip>
    <isin>US8574927062</isin>
    <meetingDate>12/06/2024</meetingDate>
    <voteDescription>To Elect a Board of Trustees: Donna M. Rapaccioli</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14893374.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14893374.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>State Street Institutional Investment Trust</issuerName>
    <cusip>857492706</cusip>
    <isin>US8574927062</isin>
    <meetingDate>12/06/2024</meetingDate>
    <voteDescription>To Elect a Board of Trustees: Margaret K. McLaughlin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14893374.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14893374.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>State Street Institutional Investment Trust</issuerName>
    <cusip>857492706</cusip>
    <isin>US8574927062</isin>
    <meetingDate>12/06/2024</meetingDate>
    <voteDescription>To Elect a Board of Trustees: George M. Pereira</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14893374.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14893374.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>State Street Institutional Investment Trust</issuerName>
    <cusip>857492706</cusip>
    <isin>US8574927062</isin>
    <meetingDate>12/06/2024</meetingDate>
    <voteDescription>To Elect a Board of Trustees: Mark E. Swanson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14893374.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14893374.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>State Street Institutional Investment Trust</issuerName>
    <cusip>857492706</cusip>
    <isin>US8574927062</isin>
    <meetingDate>12/06/2024</meetingDate>
    <voteDescription>To Elect a Board of Trustees: Jeanne LaPorta</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14893374.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14893374.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Abeona Therapeutics Inc.</issuerName>
    <cusip>00289Y206</cusip>
    <isin>US00289Y2063</isin>
    <meetingDate>12/20/2024</meetingDate>
    <voteDescription>To approve an increase in the number of shares reserved for issuance under the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan from 3,200,000 to 8,400,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>326995.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>326995.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Abeona Therapeutics Inc.</issuerName>
    <cusip>00289Y206</cusip>
    <isin>US00289Y2063</isin>
    <meetingDate>12/20/2024</meetingDate>
    <voteDescription>To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>326995.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>326995.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Galera Therapeutics, Inc.</issuerName>
    <cusip>36338D108</cusip>
    <isin>US36338D1081</isin>
    <meetingDate>02/24/2025</meetingDate>
    <voteDescription>Election of Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified: Lawrence Alleva</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>125773.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Galera Therapeutics, Inc.</issuerName>
    <cusip>36338D108</cusip>
    <isin>US36338D1081</isin>
    <meetingDate>02/24/2025</meetingDate>
    <voteDescription>Election of Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified: Kevin Lokay</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>125773.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Galera Therapeutics, Inc.</issuerName>
    <cusip>36338D108</cusip>
    <isin>US36338D1081</isin>
    <meetingDate>02/24/2025</meetingDate>
    <voteDescription>To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>125773.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Election of Directors: Hongbo Lu</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Election of Directors: Michael S. Perry</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Election of Directors: Christopher Anzalone</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Election of Directors: Mauro Ferrari</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Election of Directors: Adeoye Olukotun</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Election of Directors: William Waddill</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Election of Directors: Victoria Vakiener</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Election of Directors: Douglas Ingram</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Advisory Vote to Approve Executive Compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>Advisory Vote on Frequency of Executive Compensation Advisory Votes.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arrowhead Pharmaceuticals, Inc.</issuerName>
    <cusip>04280A100</cusip>
    <isin>US04280A1007</isin>
    <meetingDate>03/12/2025</meetingDate>
    <voteDescription>To ratify the selection of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>222814.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>222814.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Accept Financial Statements and Statutory Reports</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Approve Dividends</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Reappoint PricewaterhouseCoopers LLP as Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Authorise Board to Fix Remuneration of Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Michel Demare as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Pascal Soriot as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Aradhana Sarin as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Philip Broadley as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Euan Ashley as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Elect Birgit Conix as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Elect Rene Haas as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Elect Karen Knudsen as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Diana Layfield as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Anna Manz as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Sheri McCoy as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Tony Mok as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Nazneen Rahman as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Re-elect Marcus Wallenberg as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Approve Remuneration Report</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Authorise UK Political Donations and Expenditure</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>OTHER SOCIAL ISSUES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Authorise Issue of Equity</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Authorise Issue of Equity without Pre-emptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital Investment</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Authorise Market Purchase of Ordinary Shares</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2025</meetingDate>
    <voteDescription>Authorise the Company to Call General Meeting with Two Weeks' Notice</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>111653.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>111653.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To re-elect Kenneth Cunningham, M.D. as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To re-elect Vikas Sinha as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To re-elect James Brady as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To re-appoint Ernst &amp; Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds7,031,895 (being up to a maximum of 140,637,892 shares representing 20% of the Company's existing ordinary share capital as at the close of business on March 11, 2025 (being the latest practicable date prior to publication of this document)).</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/24/2025</meetingDate>
    <voteDescription>To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the Companies Act does not apply to any such allotment.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>04/28/2025</meetingDate>
    <voteDescription>THAT a special resolution that the deregistration of the Company in the Cayman Islands and the continuation of the Company to Switzerland be and hereby is approved and authorized (the &quot;Continuation&quot;).</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9384.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9384.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>04/28/2025</meetingDate>
    <voteDescription>Subject to, and effective only upon, (i) the approval of Resolution 1, (ii) the de-registration of the Company from the Register of Companies in the Cayman Islands and (iii) the simultaneous registration of the Continuation with the Swiss Commercial Register, THAT: 1. The seventh amended and restated memorandum and articles of association be amended and restated in the form set forth in Exhibit A to the proxy statement/prospectus (the &quot;Proposed Swiss Articles&quot;) to be effective from the effective date of the Continuation. 2. The holders of ordinary shares represented in person or by proxy at the EGM hereby waive the option to discuss each individual article of the Proposed Swiss Articles and hereby approve the Proposed Swiss Articles in the form set forth in Exhibit A to the proxy statement/prospectus.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9384.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9384.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>04/28/2025</meetingDate>
    <voteDescription>Subject to the approval of the Continuation and as required by Swiss law, THAT the election of Ernst &amp; Young AG to serve as the Company's statutory auditor (for Swiss legal purposes) until the Company's first annual general meeting following the completion of the Continuation and provide the related audit services and the authorization to board of directors to fix the remuneration of Ernst &amp; Young AG be and hereby is approved and authorized.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9384.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9384.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Halozyme Therapeutics, Inc.</issuerName>
    <cusip>40637H109</cusip>
    <isin>US40637H1095</isin>
    <meetingDate>05/01/2025</meetingDate>
    <voteDescription>Election of Class III Directors: Jeffrey W. Henderson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>46094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>46094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Halozyme Therapeutics, Inc.</issuerName>
    <cusip>40637H109</cusip>
    <isin>US40637H1095</isin>
    <meetingDate>05/01/2025</meetingDate>
    <voteDescription>Election of Class III Directors: Helen I. Torley</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>46094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>46094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Halozyme Therapeutics, Inc.</issuerName>
    <cusip>40637H109</cusip>
    <isin>US40637H1095</isin>
    <meetingDate>05/01/2025</meetingDate>
    <voteDescription>To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>46094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>46094.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Halozyme Therapeutics, Inc.</issuerName>
    <cusip>40637H109</cusip>
    <isin>US40637H1095</isin>
    <meetingDate>05/01/2025</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>46094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>46094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish Manwani</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'Day</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony Welters</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To vote on a stockholder proposal requesting the CEO pay ratio factor be included in the Company's executive compensation programs, if properly presented at the Annual Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIVERSITY, EQUITY, AND INCLUSION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To vote on a stockholder proposal requesting a comprehensive human rights policy and human rights due diligence process, if properly presented at the Annual Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/07/2025</meetingDate>
    <voteDescription>To vote on a stockholder proposal requesting a report on the risks of the Company's DEI practices for contractors, if properly presented at the Annual Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>ENVIRONMENT OR CLIMATE</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>DIVERSITY, EQUITY, AND INCLUSION</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>OTHER SOCIAL ISSUES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>252622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>252622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/08/2025</meetingDate>
    <voteDescription>To elect the following nominees as Class III directors of Alnylam: Carolyn R. Bertozzi, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>53528.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>53528.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/08/2025</meetingDate>
    <voteDescription>To elect the following nominees as Class III directors of Alnylam: Margaret A. Hamburg, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>53528.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>53528.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/08/2025</meetingDate>
    <voteDescription>To elect the following nominees as Class III directors of Alnylam: Colleen F. Reitan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>53528.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>53528.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/08/2025</meetingDate>
    <voteDescription>To elect the following nominees as Class III directors of Alnylam: Amy W. Schulman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>53528.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>53528.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/08/2025</meetingDate>
    <voteDescription>To approve an Amendment to our Restated Certificate of Incorporation allowing for officer exculpation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>53528.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>53528.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/08/2025</meetingDate>
    <voteDescription>To approve the second amended and restated 2018 Stock Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>53528.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>53528.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/08/2025</meetingDate>
    <voteDescription>To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>53528.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>53528.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/08/2025</meetingDate>
    <voteDescription>To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>53528.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>53528.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That the annual report and accounts for the year ended December 31, 2024, together with the directors' report and independent auditor's report thereon, be received and adopted.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That PricewaterhouseCoopers LLP (&quot;PwC&quot;) be re-appointed as auditors to hold office from the conclusion of the annual general meeting until the conclusion of the next annual general meeting at which the Company's annual report and accounts are presented.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That the Audit and Risk Committee be authorized to determine PwC's remuneration.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That the directors' remuneration report (excluding the directors' remuneration policy), as set out in the Company's annual report and accounts for the year ended December 31, 2024, be approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That the frequency of future advisory votes on the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That Dr. Deepika Pakianathan be re-appointed as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That Dr. Pierre Jacquet be re-appointed as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>That Michael Wyzga be re-appointed as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1078068.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1078068.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rallybio Corporation</issuerName>
    <cusip>75120L100</cusip>
    <isin>US75120L1008</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Martin W. Mackay</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>377375.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>377375.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rallybio Corporation</issuerName>
    <cusip>75120L100</cusip>
    <isin>US75120L1008</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Paula Soteropoulos</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>377375.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>377375.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rallybio Corporation</issuerName>
    <cusip>75120L100</cusip>
    <isin>US75120L1008</isin>
    <meetingDate>05/13/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as the independent registered public accounting firm.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>377375.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>377375.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: John T. Henderson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138707.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>138707.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: B. Lynne Parshall</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138707.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138707.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: Muna Bhanji</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138707.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138707.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To approve the amendment and restatement of the Cytokinetics Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under such plan by 5,000,000 shares of common stock and (ii) provide for limitations on the maximum grant value that non-executive directors may receive under such plan of $1,000,000 for annual grants to continuing directors and $1,250,000 for the initial grant to new directors.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138707.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138707.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To approve an amendment to Cytokinetics, Incorporated's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common available for issuance by Cytokinetics, Incorporated from 163,000,000 to 326,000,000 shares of common stock.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138707.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138707.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To ratify the appointment by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as the Cytokinetics, Incorporated's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138707.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138707.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138707.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138707.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Syndax Pharmaceuticals, Inc.</issuerName>
    <cusip>87164F105</cusip>
    <isin>US87164F1057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Keith A. Katkin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>99340.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>99340.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Syndax Pharmaceuticals, Inc.</issuerName>
    <cusip>87164F105</cusip>
    <isin>US87164F1057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Dennis G. Podlesak</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>99340.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>99340.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Syndax Pharmaceuticals, Inc.</issuerName>
    <cusip>87164F105</cusip>
    <isin>US87164F1057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Aleksandra Rizo, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>99340.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>99340.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Syndax Pharmaceuticals, Inc.</issuerName>
    <cusip>87164F105</cusip>
    <isin>US87164F1057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>99340.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>99340.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Syndax Pharmaceuticals, Inc.</issuerName>
    <cusip>87164F105</cusip>
    <isin>US87164F1057</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>To ratify the selection of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>99340.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>99340.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Sangeeta Bhatia</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Lloyd Carney</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Alan Garber</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Reshma Kewalramani</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Michel Lagarde</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Jeffrey Leiden</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Diana McKenzie</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Bruce Sachs</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Jennifer Schneider</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Nancy Thornberry</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Election of Directors: Suketu Upadhyay</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Ratification of Ernst &amp; Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Advisory vote to approve named executive officer compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/14/2025</meetingDate>
    <voteDescription>Shareholder proposal, if properly presented at the meeting, regarding excessive golden parachutes.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>43156.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>43156.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of Directors: Yuval Cohen</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of Directors: Alan Holmer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of Directors: Winston Kung</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of Directors: Rachelle Jacques</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of Directors: John Jenkins</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of Directors: Anne Altmeyer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of Directors: Yong Ben</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Ratification of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26894.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>26894.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders: Leo Lee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125361.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>125361.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Election of two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders: William H. Lewis</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125361.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>125361.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>An advisory vote on the 2024 compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125361.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>125361.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125361.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>125361.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Approval of Amendment No. 2 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>125361.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>125361.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Roy Baynes</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Suzanne Bruhn</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Timothy Coughlin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Eric Dube</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Gary Lyons</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Jeffrey Meckler</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: John Orwin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Sandra Poole</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ron Squarer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ruth Williams-Brinkley</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To approve the Company's 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Travere Therapeutics, Inc.</issuerName>
    <cusip>89422G107</cusip>
    <isin>US89422G1076</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>127724.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>127724.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Nominees: Matthew K. Fust</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>143437.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>143437.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Nominees: Amrit Ray, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>143437.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>143437.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Approval of the Second Amended and Restated 2023 Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>143437.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>143437.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Ratification of the selection of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>143437.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>143437.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>05/15/2025</meetingDate>
    <voteDescription>Advisory (non-binding) vote to approve the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>143437.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>143437.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Approve Allocation of Income and Omission of Dividends</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101845.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>101845.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Approve Discharge of Management Board for Fiscal Year 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101845.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>101845.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Approve Discharge of Supervisory Board for Fiscal Year 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101845.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>101845.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Ratify EY GmbH &amp; Co. KG as Auditors for Fiscal Year 2025</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101845.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>101845.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Appoint EY GmbH &amp; Co. KG as Auditor for Sustainability Reporting for Fiscal Year 2025</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101845.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>101845.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Approve Remuneration Report</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101845.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>101845.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Approve Creation of EUR 124.3 Million Pool of Authorized Capital with or without Exclusion of Preemptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101845.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>101845.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Election of Class II Directors: Daniel S. Janney</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18573.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>18573.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Election of Class II Directors: Dino A. Rossi</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18573.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>18573.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Election of Class II Directors: E. Rand Sutherland</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18573.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>18573.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18573.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>18573.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18573.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>18573.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Election of Directors: August J. Troendle</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7343.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7343.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Election of Directors: Dani S. Zander</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7343.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7343.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7343.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>7343.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2025 Annual Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7343.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>7343.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>To approve the Medpace Holdings, Inc. 2016 Amended and Restated Incentive Award Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7343.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7343.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Stockholder proposal regarding implementation of simple majority voting, if properly presented at the meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>7343.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7343.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Personalis, Inc.</issuerName>
    <cusip>71535D106</cusip>
    <isin>US71535D1063</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Election of Directors: A. Blaine Bowman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>864899.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>864899.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Personalis, Inc.</issuerName>
    <cusip>71535D106</cusip>
    <isin>US71535D1063</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Election of Directors: Karin Eastham</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>864899.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>864899.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Personalis, Inc.</issuerName>
    <cusip>71535D106</cusip>
    <isin>US71535D1063</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Ratification of the selection by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>864899.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>864899.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Personalis, Inc.</issuerName>
    <cusip>71535D106</cusip>
    <isin>US71535D1063</isin>
    <meetingDate>05/16/2025</meetingDate>
    <voteDescription>Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>864899.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>864899.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Abeona Therapeutics Inc.</issuerName>
    <cusip>00289Y206</cusip>
    <isin>US00289Y2063</isin>
    <meetingDate>05/19/2025</meetingDate>
    <voteDescription>Election of three Class 3 Directors for a three-year term: Mark J. Alvino</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>224356.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>224356.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Abeona Therapeutics Inc.</issuerName>
    <cusip>00289Y206</cusip>
    <isin>US00289Y2063</isin>
    <meetingDate>05/19/2025</meetingDate>
    <voteDescription>Election of three Class 3 Directors for a three-year term: Faith L. Charles</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>224356.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>224356.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Abeona Therapeutics Inc.</issuerName>
    <cusip>00289Y206</cusip>
    <isin>US00289Y2063</isin>
    <meetingDate>05/19/2025</meetingDate>
    <voteDescription>Election of three Class 3 Directors for a three-year term: Donald A. Wuchterl</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>224356.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>224356.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Abeona Therapeutics Inc.</issuerName>
    <cusip>00289Y206</cusip>
    <isin>US00289Y2063</isin>
    <meetingDate>05/19/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>224356.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>224356.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Abeona Therapeutics Inc.</issuerName>
    <cusip>00289Y206</cusip>
    <isin>US00289Y2063</isin>
    <meetingDate>05/19/2025</meetingDate>
    <voteDescription>Ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accountant for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>224356.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>224356.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Elizabeth M. Anderson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Barbara W. Bodem</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Athena Countouriotis</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Willard Dere</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Mark J. Enyedy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Alexander Hardy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Maykin Ho</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Robert J. Hombach</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Richard A. Meier</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>Election of Directors: Timothy P. Walbert</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>192503.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>192503.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Eric Lefkofsky</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Peter J. Barris</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Eric D. Belcher</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Jennifer A. Doudna</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: David R. Epstein</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Wayne A.I. Frederick, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Scott Gottlieb, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Theodore J. Leonsis</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Nadja West, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To ratify the appointment by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tempus AI, Inc.</issuerName>
    <cusip>88023B103</cusip>
    <isin>US88023B1035</isin>
    <meetingDate>05/20/2025</meetingDate>
    <voteDescription>To approve the reincorporation of the Company from the State of Delaware to the State of Nevada by conversion.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>96221.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>96221.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Shane M. Cooke</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Richard B. Gaynor, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Cato T. Laurencin, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Nancy S. Lurker</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Brian P. McKeon</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Richard F. Pops</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Nancy L. Snyderman, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Frank Anders Wilson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Christopher I. Wright, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To renew Board authority to allot and issue shares under Irish law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67632.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>67632.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arbutus Biopharma Corporation</issuerName>
    <cusip>03879J100</cusip>
    <isin>CA03879J1003</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Lindsay Androski, JD, MBA, CFA</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>342379.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>342379.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arbutus Biopharma Corporation</issuerName>
    <cusip>03879J100</cusip>
    <isin>CA03879J1003</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Robert Alan Beardsley</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>342379.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>342379.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arbutus Biopharma Corporation</issuerName>
    <cusip>03879J100</cusip>
    <isin>CA03879J1003</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Joseph Bishop</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>342379.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>342379.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arbutus Biopharma Corporation</issuerName>
    <cusip>03879J100</cusip>
    <isin>CA03879J1003</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew Gline</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>342379.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>342379.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arbutus Biopharma Corporation</issuerName>
    <cusip>03879J100</cusip>
    <isin>CA03879J1003</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Anuj Hasija</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>342379.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>342379.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arbutus Biopharma Corporation</issuerName>
    <cusip>03879J100</cusip>
    <isin>CA03879J1003</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>342379.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>342379.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arbutus Biopharma Corporation</issuerName>
    <cusip>03879J100</cusip>
    <isin>CA03879J1003</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>342379.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>342379.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Geron Corporation</issuerName>
    <cusip>374163103</cusip>
    <isin>US3741631036</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect the two nominees for director named below to hold office as Class II members of the Board of Directors until the 2028 annual meeting of stockholders: Dawn C. Bir</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1360622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1360622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Geron Corporation</issuerName>
    <cusip>374163103</cusip>
    <isin>US3741631036</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To elect the two nominees for director named below to hold office as Class II members of the Board of Directors until the 2028 annual meeting of stockholders: Elizabeth G. O'Farrell</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1360622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1360622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Geron Corporation</issuerName>
    <cusip>374163103</cusip>
    <isin>US3741631036</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve an amendment to our 2018 Equity Incentive Plan to, among other items, increase the total number of shares of our common stock issuable thereunder by 20,000,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1360622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1360622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Geron Corporation</issuerName>
    <cusip>374163103</cusip>
    <isin>US3741631036</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve an amendment to our 2014 Employee Stock Purchase Plan to increase the number of shares of our common stock issuable thereunder by 6,000,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1360622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1360622.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Geron Corporation</issuerName>
    <cusip>374163103</cusip>
    <isin>US3741631036</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1360622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1360622.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Geron Corporation</issuerName>
    <cusip>374163103</cusip>
    <isin>US3741631036</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1360622.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1360622.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Frances Arnold, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Caroline D. Dorsa</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Robert S. Epstein, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Scott Gottlieb, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Gary S. Guthart, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Keith A. Meister</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Anna Richo</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Philip W. Schiller</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Susan E. Siegel</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Jacob Thaysen, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Election of Directors: Scott B. Ullem</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 28, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve the Second Amended and Restated 2015 Stock and Incentive Plan of Illumina, Inc.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72264.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72264.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Adoption of Merus N.V.'s Dutch statutory annual accounts for the financial year 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Appointment of KPMG Accountants N.V. as Merus N.V.'s external auditor for the financial year 2025 for purposes of Dutch law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Release of each member of Merus N.V.'s board of directors from liability for the exercise of their duties during the financial year 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Opportunity to make recommendations for nomination by Merus N.V.'s group of non-executive directors.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Re-appointment of Anand Mehra, M.D. as non-executive director.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Opportunity to make recommendations for nomination by Merus N.V.'s group of non-executive directors.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Re-appointment of Maxine Gowen, Ph.D. as non-executive director.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Granting authorization to Merus N.V.'s board of directors to acquire shares (or depository receipts for such shares) in Merus N.V.'s capital.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Merus N.V.</issuerName>
    <cusip>N5749R100</cusip>
    <isin>NL0011606264</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50620.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>50620.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Kyle W. Gano, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>56639.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>56639.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Richard F. Pops</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>56639.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>56639.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Shalini Sharp</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>56639.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>56639.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Stephen A. Sherwin, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>56639.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>56639.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>Advisory vote on the compensation paid to the Company's named executive officers;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>56639.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>56639.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve the Company's 2025 Equity Incentive Plan;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>56639.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>56639.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To approve an amendment and restatement of the Company's 2018 Employee Stock Purchase Plan; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>56639.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>56639.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/21/2025</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>56639.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>56639.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SCHOLAR ROCK HOLDING CORPORATION</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>05/22/2025</meetingDate>
    <voteDescription>To elect three Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Srinivas Akkaraju, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32760.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>32760.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SCHOLAR ROCK HOLDING CORPORATION</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>05/22/2025</meetingDate>
    <voteDescription>To elect three Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Joshua Reed</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32760.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>32760.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SCHOLAR ROCK HOLDING CORPORATION</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>05/22/2025</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32760.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>32760.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vigil Neuroscience, Inc.</issuerName>
    <cusip>92673K108</cusip>
    <isin>US92673K1088</isin>
    <meetingDate>05/22/2025</meetingDate>
    <voteDescription>To elect two class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his, her or their successor has been duly elected and qualified, or until his, her or their earlier death, resignation or removal: Samantha Budd Haeberlein, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1545378.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>1545378.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vigil Neuroscience, Inc.</issuerName>
    <cusip>92673K108</cusip>
    <isin>US92673K1088</isin>
    <meetingDate>05/22/2025</meetingDate>
    <voteDescription>To elect two class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his, her or their successor has been duly elected and qualified, or until his, her or their earlier death, resignation or removal: Gerhard Koenig, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1545378.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>1545378.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vigil Neuroscience, Inc.</issuerName>
    <cusip>92673K108</cusip>
    <isin>US92673K1088</isin>
    <meetingDate>05/22/2025</meetingDate>
    <voteDescription>To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1545378.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1545378.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. Austin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Bradway</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. Drake</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. Druker</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Eckert</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. Garland</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar Ishrak</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler Jacks</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. Klotman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. Kullman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. Miles</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>Advisory vote to approve our executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/23/2025</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>103290.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>103290.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Approve Remuneration Report</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16111.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16111.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Adopt Financial Statements and Statutory Reports</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16111.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16111.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Approve Allocation of Income to the Retained Earnings of the Company</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16111.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16111.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Approve Discharge of Directors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16111.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16111.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Approve Remuneration Policy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16111.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16111.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Reelect Anthony Rosenberg as Non-Executive Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16111.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16111.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Grant Board Authority to Issue Shares and Exclude Pre-emptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16111.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16111.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Elect Lars Luthjohan as Chair of Meeting</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Accept Financial Statements and Statutory Reports; Approve Discharge of Management and Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Approve Treatment of Net Loss</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Reelect Albert Cha as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Reelect Lars Holtug as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Reelect Jan Moller Mikkelsen as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Reelect Lisa Jane Morrison as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Reelect William Carl Fairey Jr as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Reelect Siham Imani as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Ratify Deloitte as Auditor</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Approve Creation of DKK 3.8 Million Pool of Capital without Preemptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Approve Issuance of Warrants to Board Members</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/27/2025</meetingDate>
    <voteDescription>Amend Articles Re: Board-Related</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47233.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47233.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tenaya Therapeutics, Inc.</issuerName>
    <cusip>87990A106</cusip>
    <isin>US87990A1060</isin>
    <meetingDate>05/28/2025</meetingDate>
    <voteDescription>To elect three Class I directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: David Goeddel, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>600700.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>600700.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tenaya Therapeutics, Inc.</issuerName>
    <cusip>87990A106</cusip>
    <isin>US87990A1060</isin>
    <meetingDate>05/28/2025</meetingDate>
    <voteDescription>To elect three Class I directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: Jeffrey T. Walsh, M.B.A.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>600700.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>600700.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tenaya Therapeutics, Inc.</issuerName>
    <cusip>87990A106</cusip>
    <isin>US87990A1060</isin>
    <meetingDate>05/28/2025</meetingDate>
    <voteDescription>To elect three Class I directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: R. Sanders Williams, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>600700.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>600700.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tenaya Therapeutics, Inc.</issuerName>
    <cusip>87990A106</cusip>
    <isin>US87990A1060</isin>
    <meetingDate>05/28/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>600700.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>600700.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>GRAIL, Inc.</issuerName>
    <cusip>384747101</cusip>
    <isin>US3847471014</isin>
    <meetingDate>05/29/2025</meetingDate>
    <voteDescription>Election of Class I Director to serve until the 2028 Annual Meeting of Stockholders, and until their respective successor has been duly elected and qualified: William (Bill) Chase</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>86408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>86408.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>GRAIL, Inc.</issuerName>
    <cusip>384747101</cusip>
    <isin>US3847471014</isin>
    <meetingDate>05/29/2025</meetingDate>
    <voteDescription>The ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>86408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>86408.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vir Biotechnology, Inc.</issuerName>
    <cusip>92764N102</cusip>
    <isin>US92764N1028</isin>
    <meetingDate>05/29/2025</meetingDate>
    <voteDescription>To elect the following two nominees for director to hold office until the 2028 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Jeffrey S. Hatfield</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216154.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>216154.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vir Biotechnology, Inc.</issuerName>
    <cusip>92764N102</cusip>
    <isin>US92764N1028</isin>
    <meetingDate>05/29/2025</meetingDate>
    <voteDescription>To elect the following two nominees for director to hold office until the 2028 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Saira Ramasastry</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216154.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>216154.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vir Biotechnology, Inc.</issuerName>
    <cusip>92764N102</cusip>
    <isin>US92764N1028</isin>
    <meetingDate>05/29/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216154.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>216154.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vir Biotechnology, Inc.</issuerName>
    <cusip>92764N102</cusip>
    <isin>US92764N1028</isin>
    <meetingDate>05/29/2025</meetingDate>
    <voteDescription>To ratify the appointment by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216154.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>216154.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Dyne Therapeutics, Inc.</issuerName>
    <cusip>26818M108</cusip>
    <isin>US26818M1080</isin>
    <meetingDate>05/30/2025</meetingDate>
    <voteDescription>To elect two Class II directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Edward Hurwitz</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>314586.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>314586.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Dyne Therapeutics, Inc.</issuerName>
    <cusip>26818M108</cusip>
    <isin>US26818M1080</isin>
    <meetingDate>05/30/2025</meetingDate>
    <voteDescription>To elect two Class II directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Dirk Kersten</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>314586.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>314586.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Dyne Therapeutics, Inc.</issuerName>
    <cusip>26818M108</cusip>
    <isin>US26818M1080</isin>
    <meetingDate>05/30/2025</meetingDate>
    <voteDescription>To vote, on an advisory basis, to approve the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>314586.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>314586.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Dyne Therapeutics, Inc.</issuerName>
    <cusip>26818M108</cusip>
    <isin>US26818M1080</isin>
    <meetingDate>05/30/2025</meetingDate>
    <voteDescription>To hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>314586.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>314586.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Dyne Therapeutics, Inc.</issuerName>
    <cusip>26818M108</cusip>
    <isin>US26818M1080</isin>
    <meetingDate>05/30/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>314586.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>314586.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oruka Therapeutics, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>06/02/2025</meetingDate>
    <voteDescription>Election of Class I Directors for terms expiring in 2028: Carl Dambkowski, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2705.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2705.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oruka Therapeutics, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>06/02/2025</meetingDate>
    <voteDescription>Election of Class I Directors for terms expiring in 2028: Peter Harwin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2705.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2705.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oruka Therapeutics, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>06/02/2025</meetingDate>
    <voteDescription>To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Oruka Therapeutics, Inc. for its fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2705.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2705.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oruka Therapeutics, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>06/02/2025</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2705.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2705.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oruka Therapeutics, Inc.</issuerName>
    <cusip>687604108</cusip>
    <isin>US6876041087</isin>
    <meetingDate>06/02/2025</meetingDate>
    <voteDescription>To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2705.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>2705.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Judy Chou, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>164668.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>164668.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Tomas Heyman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>164668.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>164668.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>164668.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>164668.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>164668.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>164668.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Julian Baker</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>337505.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>337505.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Peter Klein</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>337505.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>337505.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Steve Krognes</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>337505.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>337505.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>337505.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>337505.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>06/03/2025</meetingDate>
    <voteDescription>Advisory vote on executive compensation</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>337505.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>337505.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunic, Inc.</issuerName>
    <cusip>4525EP101</cusip>
    <isin>US4525EP1011</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Election of Directors for a term expiring at the 2028 Annual Meeting of Stockholders: Dr. Jorg Neermann</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2679817.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>2679817.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunic, Inc.</issuerName>
    <cusip>4525EP101</cusip>
    <isin>US4525EP1011</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Election of Directors for a term expiring at the 2028 Annual Meeting of Stockholders: Ms. Tamar Howson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2679817.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2679817.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunic, Inc.</issuerName>
    <cusip>4525EP101</cusip>
    <isin>US4525EP1011</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Election of Directors for a term expiring at the 2028 Annual Meeting of Stockholders: Mr. Barclay Phillips</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2679817.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2679817.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunic, Inc.</issuerName>
    <cusip>4525EP101</cusip>
    <isin>US4525EP1011</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Amendment to the Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as Amended, to increase the number of shares of common stock authorized for issuance by 7,000,000 shares to a total of 26,448,871 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2679817.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>2679817.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immunic, Inc.</issuerName>
    <cusip>4525EP101</cusip>
    <isin>US4525EP1011</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Ratification of appointment of Baker Tilly US, LLP as our independent registered public accounting firm for fiscal year ending December 31, 2025</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2679817.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2679817.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Instruction to Deloitte Accountants B.V. as the Company's external auditor of the Company's Dutch statutory annual accounts and Dutch statutory board report for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Ratification of the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the audit committee of the Company's Board of Directors.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Wouter Joustra</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Mark McKenna</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Adele Gulfo</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director of the Company until the 2029 annual general meeting: Michael Davidson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director of the Company until the 2029 annual general meeting: James N. Topper</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Extension of authorization for the Board of Directors to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Non-binding, advisory vote to approve the 2024 compensation of named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NewAmsterdam Pharma Company N.V.</issuerName>
    <cusip>N62509109</cusip>
    <isin>NL00150012L7</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>116590.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>116590.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Accept Financial Statements and Statutory Reports</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Treatment of Net Loss</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Discharge of Board and Senior Management</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reelect Anthony Rosenberg as Director and Board Chair</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reelect Christina Ackermann as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reelect Lionel Carnot as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reelect Arshad Khanani as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reelect Martijn Kleijwegt as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reelect Geraldine O'Keeffe as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reelect Riad Sherif as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reelect Robert Warner as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reappoint Christina Ackermann as Member of the Compensation Committee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Reappoint Lionel Carnot as Member of the Compensation Committee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Appoint Robert Warner as Member of the Compensation Committee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Ratify PricewaterhouseCoopers SA as Statutory Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Designate PST Legal AG as Independent Proxy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Fixed Remuneration of Directors in the Amount of USD 572,000</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Equity-Based Remuneration of Directors in the Amount of USD 2.2 Million</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Fixed Remuneration of Executive Committee in the Amount of USD 2.5 Million</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Variable Remuneration of Executive Committee in the Amount of USD 1.8 Million</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Equity-Based Remuneration of Executive Committee in the Amount of USD 15.5 Million</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Remuneration Report (Non-Binding)</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Creation of Capital Band within the Upper Limit of CHF 818,005 and the Lower Limit of CHF 545,337 with or without Exclusion of Preemptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Approve Creation of CHF 124,800 Pool of Conditional Capital for Employee Equity Plans</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>Transact Other Business (Voting)</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Dawn Svoronos</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gillian Cannon</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Steven Gannon</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Elizabeth Garofalo</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Justin Gover</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Patrick Machado</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Ian Mortimer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gary Patou</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Corporation's named executive officers;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To appoint PricewaterhouseCoopers LLP (&quot;PwC&quot;) as the Corporation's auditor to hold office until the next annual meeting of the Corporation;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2025</meetingDate>
    <voteDescription>To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditors of the Corporation;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>168006.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>168006.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Karen Firestone</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>762240.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>762240.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Justin Klee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>762240.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>762240.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Bernhardt Zeiher, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>762240.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>762240.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>762240.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>762240.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executives officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>762240.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>762240.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of Directors: Allene M. Diaz</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>128658.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>128658.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of Directors: Michael Hayden</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>128658.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>128658.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of Directors: Joseph Klein, III</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>128658.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>128658.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of Directors: Joseph Loscalzo</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>128658.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>128658.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>To make an advisory vote on executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>128658.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>128658.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 4,000,000 shares to an aggregate of 42,500,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>128658.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>128658.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>To ratify the Audit Committee's selection of Ernst &amp; Young LLP as independent auditors for the 2025 fiscal year.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>128658.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>128658.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of three directors to serve until the company's 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified: Michael Dybbs, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of three directors to serve until the company's 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified: Simeon George, M. D., M.B.A.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Election of three directors to serve until the company's 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified: Leone Patterson, M.B.A.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as the company's independent registered public accounting firm for the year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: RICHARD J. BARRY</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>135231.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>135231.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: M. KATHLEEN BEHRENS, PH.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>135231.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>135231.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: STEPHEN L. MAYO, PH.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>135231.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>135231.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: CLAUDE NICAISE, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>135231.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>135231.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>135231.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>135231.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>APPROVE AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN (THE &quot;2018 PLAN&quot;) TO INCREASE THE MAXIMUM AGGREGATE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED PURSUANT TO AWARDS GRANTED UNDER THE 2018 PLAN BY 4,300,000 SHARES TO 17,487,596 SHARES</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>135231.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>135231.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>APPROVE AN AMENDMENT TO THE AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON JUNE 27, 2016, AND AMENDED ON JUNE 6, 2019 AND ON JUNE 8, 2023) (THE &quot;2016 ESPP&quot;) TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2016 ESPP BY 300,000 SHARES TO 1,700,000 SHARES</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>135231.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>135231.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/05/2025</meetingDate>
    <voteDescription>RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT YEAR ENDING DECEMBER 31, 2025</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>135231.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>135231.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Axsome Therapeutics, Inc.</issuerName>
    <cusip>05464T104</cusip>
    <isin>US05464T1043</isin>
    <meetingDate>06/06/2025</meetingDate>
    <voteDescription>Election of Director: Roger Jeffs, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35052.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>35052.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Axsome Therapeutics, Inc.</issuerName>
    <cusip>05464T104</cusip>
    <isin>US05464T1043</isin>
    <meetingDate>06/06/2025</meetingDate>
    <voteDescription>To approve the Company's 2025 Long-Term Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35052.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>35052.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Axsome Therapeutics, Inc.</issuerName>
    <cusip>05464T104</cusip>
    <isin>US05464T1043</isin>
    <meetingDate>06/06/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35052.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35052.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Axsome Therapeutics, Inc.</issuerName>
    <cusip>05464T104</cusip>
    <isin>US05464T1043</isin>
    <meetingDate>06/06/2025</meetingDate>
    <voteDescription>To approve, by non-binding advisory vote, the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35052.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35052.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Adaptive Biotechnologies Corporation</issuerName>
    <cusip>00650F109</cusip>
    <isin>US00650F1093</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect one Class III director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2028 annual meeting of shareholders: Chad Robins</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>482420.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>482420.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Adaptive Biotechnologies Corporation</issuerName>
    <cusip>00650F109</cusip>
    <isin>US00650F1093</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>482420.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>482420.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Adaptive Biotechnologies Corporation</issuerName>
    <cusip>00650F109</cusip>
    <isin>US00650F1093</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the year ending December 31, 2025; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>482420.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>482420.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Arthur Levin, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138274.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138274.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Simona Skerjanec</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138274.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138274.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Tamar Thompson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138274.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>138274.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent public accounting firm for the fiscal year ending December 31, 2025;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138274.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>138274.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>138274.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>138274.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>Election of the two Class III directors named in the Proxy Statement to hold office for a three-year term expiring at the 2028 Annual Meeting: David V. Smith</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>606294.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>606294.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>Election of the two Class III directors named in the Proxy Statement to hold office for a three-year term expiring at the 2028 Annual Meeting: Dennis P. Wolf</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>606294.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>606294.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>606294.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>606294.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>606294.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>606294.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To approve an amendment to the Codexis, Inc. 2019 Incentive Award Plan to increase the number of shares available for issuance thereunder by 8,000,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>606294.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>606294.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: lain Dukes, D. Phil.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Ryan Maynard</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wayne P. Rothbaum</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wendy Yarno</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To approve, by non-binding advisory vote, the compensation of our named executive officers;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 12,500,000 shares; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Iovance Biotherapeutics, Inc.</issuerName>
    <cusip>462260100</cusip>
    <isin>US4622601007</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,000,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>131800.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>131800.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>LENZ Therapeutics, Inc.</issuerName>
    <cusip>52635N103</cusip>
    <isin>US52635N1037</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and two Class I directors to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified: Class III: Kimberlee C. Drapkin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>15035.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>15035.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>LENZ Therapeutics, Inc.</issuerName>
    <cusip>52635N103</cusip>
    <isin>US52635N1037</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and two Class I directors to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified: Class III: Zach Scheiner</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>15035.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>15035.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>LENZ Therapeutics, Inc.</issuerName>
    <cusip>52635N103</cusip>
    <isin>US52635N1037</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and two Class I directors to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified: Class I: Frederic Guerard</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>15035.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>15035.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>LENZ Therapeutics, Inc.</issuerName>
    <cusip>52635N103</cusip>
    <isin>US52635N1037</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and two Class I directors to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified: Class I: James McCollum</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>15035.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>15035.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>LENZ Therapeutics, Inc.</issuerName>
    <cusip>52635N103</cusip>
    <isin>US52635N1037</isin>
    <meetingDate>06/10/2025</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>15035.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>15035.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Election of Directors: Scott Garland</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Election of Directors: Barbara Klencke, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Advisory vote to approve named executive officer compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for our fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Matthew K. Fust</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>112408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>112408.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: R. Scott Struthers, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>112408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>112408.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Rogerio Vivaldi Coelho, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>112408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>112408.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>112408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>112408.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>112408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>112408.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Disc Medicine, Inc.</issuerName>
    <cusip>254604101</cusip>
    <isin>US2546041011</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect each of the following Class II nominees to the Board of Directors as set forth below: Georges Gemayel, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32061.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32061.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Disc Medicine, Inc.</issuerName>
    <cusip>254604101</cusip>
    <isin>US2546041011</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect each of the following Class II nominees to the Board of Directors as set forth below: Mark Chin, M.S., M.B.A.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32061.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32061.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Disc Medicine, Inc.</issuerName>
    <cusip>254604101</cusip>
    <isin>US2546041011</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect each of the following Class II nominees to the Board of Directors as set forth below: Liam Ratcliffe, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32061.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>32061.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Disc Medicine, Inc.</issuerName>
    <cusip>254604101</cusip>
    <isin>US2546041011</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32061.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>32061.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Disc Medicine, Inc.</issuerName>
    <cusip>254604101</cusip>
    <isin>US2546041011</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32061.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>32061.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Disc Medicine, Inc.</issuerName>
    <cusip>254604101</cusip>
    <isin>US2546041011</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To ratify the appointment of Emst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32061.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32061.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Janux Therapeutics, Inc.</issuerName>
    <cusip>47103J105</cusip>
    <isin>US47103J1051</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Ronald Barrett, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71237.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>71237.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Janux Therapeutics, Inc.</issuerName>
    <cusip>47103J105</cusip>
    <isin>US47103J1051</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: David Campbell, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71237.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>71237.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Janux Therapeutics, Inc.</issuerName>
    <cusip>47103J105</cusip>
    <isin>US47103J1051</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Winston Kung</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71237.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>71237.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Janux Therapeutics, Inc.</issuerName>
    <cusip>47103J105</cusip>
    <isin>US47103J1051</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71237.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>71237.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Janux Therapeutics, Inc.</issuerName>
    <cusip>47103J105</cusip>
    <isin>US47103J1051</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Approval, on an advisory basis, of the compensation of our named executive officers (&quot;Say-On-Pay&quot;), as disclosed in the accompanying Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71237.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>71237.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Janux Therapeutics, Inc.</issuerName>
    <cusip>47103J105</cusip>
    <isin>US47103J1051</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71237.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>71237.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Korro Bio, Inc.</issuerName>
    <cusip>500946108</cusip>
    <isin>US5009461089</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Election of three Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Ram Aiyar</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>84428.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>84428.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Korro Bio, Inc.</issuerName>
    <cusip>500946108</cusip>
    <isin>US5009461089</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Election of three Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Jean-Francois Formela</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>84428.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>84428.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Korro Bio, Inc.</issuerName>
    <cusip>500946108</cusip>
    <isin>US5009461089</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Election of three Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Katharine Knobil</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>84428.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>84428.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Korro Bio, Inc.</issuerName>
    <cusip>500946108</cusip>
    <isin>US5009461089</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Non-Binding Advisory Vote to Approve the Compensation of our Named Executive Officers;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>84428.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>84428.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Korro Bio, Inc.</issuerName>
    <cusip>500946108</cusip>
    <isin>US5009461089</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Non-Binding Advisory Vote on the Frequency of Future Non-Binding Advisory Votes to Approve the Compensation of our Named Executive Officers</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>84428.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>84428.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Korro Bio, Inc.</issuerName>
    <cusip>500946108</cusip>
    <isin>US5009461089</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>84428.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>84428.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Francis Cuss</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: George Golumbeski</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Benjamin Hickey</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Scott Jackson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Caroline Loew</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Sachiyo Minegishi</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>To ratify, in a non-binding advisory vote, the selection of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent auditor's remuneration;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Adoption of the 2024 Dutch statutory annual accounts for the fiscal year ended December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Discharge of liability of the members of the Board for their management during the fiscal year ended December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Reappointment of Robert Gut, M.D., Ph.D. as non-executive director.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Reappointment of Matthew Kapusta as executive director.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Reappointment of Jeremy Springhorn, Ph.D. as non-executive director.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Authorization of the Board to issue Ordinary Shares and grant rights to subscribe for Ordinary Shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Authorization of the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Authorization of the Board to repurchase Ordinary Shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Appointment of KPMG as external auditor of the Company for the financial year 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Approval, on an advisory basis, of the compensation of the named executive officers of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/11/2025</meetingDate>
    <voteDescription>Resolution to adopt the Amendment and Restatement of the 2014 Share Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>674471.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>674471.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Election of Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Bhaskar Chaudhuri, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218107.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>218107.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Election of Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Sue-Jean Lin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218107.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>218107.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Election of Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Howard G. Welgus, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218107.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>218107.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst &amp; Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218107.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218107.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218107.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>218107.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect two Class I directors to serve until the Company's 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation or removal. The two nominees for election are: Scott Braunstein, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>611144.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>611144.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect two Class I directors to serve until the Company's 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation or removal. The two nominees for election are: Ran Zheng, M.S.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>611144.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>611144.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>611144.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>611144.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To approve an amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from any whole number between 1-for-5 and 1-for-50, inclusive, as determined by the Board of Directors in its discretion, subject to the Board of Directors' authority to abandon such amendment in its discretion.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>611144.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>611144.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To approve the adjournment of the 2025 Annual Meeting to a later date or dates, if necessary, to permit further solicitation and voting of proxies in the event there are not sufficient votes in favor of any of proposals 1-3 above or if there are not sufficient shares present to establish a quorum.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>611144.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>611144.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sionna Therapeutics, Inc.</issuerName>
    <cusip>829401108</cusip>
    <isin>US8294011080</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Joshua Resnick, M.D., M.B.A.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>247000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>247000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sionna Therapeutics, Inc.</issuerName>
    <cusip>829401108</cusip>
    <isin>US8294011080</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Bruce Booth, D.Phil.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>247000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>247000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sionna Therapeutics, Inc.</issuerName>
    <cusip>829401108</cusip>
    <isin>US8294011080</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Lucian Iancovici, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>247000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>247000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sionna Therapeutics, Inc.</issuerName>
    <cusip>829401108</cusip>
    <isin>US8294011080</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>247000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>247000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Robert W. Duggan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Mahkam Zanganeh</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Manmeet S. Soni</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Kenneth A. Clark</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Robert Booth</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Alessandra Cesano</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Yu (Michelle) Xia</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Mostafa Ronaghi</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Jeff Huber</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Summit Therapeutics Inc.</issuerName>
    <cusip>86627T108</cusip>
    <isin>US86627T1088</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Approval, by a non-binding advisory vote, of the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412254.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>412254.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tarsus Pharmaceuticals, Inc.</issuerName>
    <cusip>87650L103</cusip>
    <isin>US87650L1035</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect Class II directors, to serve until the 2028 annual meeting of stockholders or until their respective successor have been elected or appointed: Bobak Azamian</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44092.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44092.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tarsus Pharmaceuticals, Inc.</issuerName>
    <cusip>87650L103</cusip>
    <isin>US87650L1035</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect Class II directors, to serve until the 2028 annual meeting of stockholders or until their respective successor have been elected or appointed: Katherine Goodrich</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44092.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44092.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tarsus Pharmaceuticals, Inc.</issuerName>
    <cusip>87650L103</cusip>
    <isin>US87650L1035</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44092.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>44092.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tarsus Pharmaceuticals, Inc.</issuerName>
    <cusip>87650L103</cusip>
    <isin>US87650L1035</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To hold an advisory vote to approve, on a non-binding basis, the frequency with which future stockholder votes on the compensation of our named executive officers will be conducted of one, two or three years.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44092.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>44092.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tarsus Pharmaceuticals, Inc.</issuerName>
    <cusip>87650L103</cusip>
    <isin>US87650L1035</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44092.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44092.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: John Furey</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>98942.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>98942.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Jacks Lee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>98942.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>98942.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Heath Lukatch, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>98942.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>98942.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>98942.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>98942.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>98942.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>98942.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>Approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to provide for officer exculpation as permitted by recent amendments to the Delaware General Corporation Law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>98942.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>98942.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Bassil I. Dahiyat</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Ellen G. Feigal</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Kevin C. Gorman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Kurt A. Gustafson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Barbara Klencke</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. A. Bruce Montgomery</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Richard J. Ranieri</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Todd E. Simpson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To approve the proposed amendment and restatement of the Company's 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 3,000,000 shares;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/12/2025</meetingDate>
    <voteDescription>To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185509.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185509.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Edgewise Therapeutics, Inc.</issuerName>
    <cusip>28036F105</cusip>
    <isin>US28036F1057</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Elect the directors named in the attached Proxy Statement to serve until the 2028 Annual Meeting of Stockholders: Alan Russell, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>153049.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>153049.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Edgewise Therapeutics, Inc.</issuerName>
    <cusip>28036F105</cusip>
    <isin>US28036F1057</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Elect the directors named in the attached Proxy Statement to serve until the 2028 Annual Meeting of Stockholders: Arlene Morris</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>153049.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>153049.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Edgewise Therapeutics, Inc.</issuerName>
    <cusip>28036F105</cusip>
    <isin>US28036F1057</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>153049.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>153049.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Edgewise Therapeutics, Inc.</issuerName>
    <cusip>28036F105</cusip>
    <isin>US28036F1057</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Conduct an advisory vote on the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>153049.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>153049.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Edgewise Therapeutics, Inc.</issuerName>
    <cusip>28036F105</cusip>
    <isin>US28036F1057</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>153049.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>153049.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Election of Directors: Bonnie L. Bassler, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Election of Directors: Michael S. Brown, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Election of Directors: Leonard S. Schleifer, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Election of Directors: George D. Yancopoulos, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Proposal to approve, on an advisory basis, executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Proposal to approve an amendment to the Company's Certificate of Incorporation to declassify the board of directors.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SHAREHOLDER RIGHTS AND DEFENSES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article IV, Section 2(e)(8) of the Certificate of Incorporation</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/13/2025</meetingDate>
    <voteDescription>Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article VI of the Certificate of Incorporation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>41502.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>41502.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Allogene Therapeutics, Inc.</issuerName>
    <cusip>019770106</cusip>
    <isin>US0197701065</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Elizabeth Barrett</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>867250.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>867250.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Allogene Therapeutics, Inc.</issuerName>
    <cusip>019770106</cusip>
    <isin>US0197701065</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Arie Belldegrun, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>867250.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>867250.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Allogene Therapeutics, Inc.</issuerName>
    <cusip>019770106</cusip>
    <isin>US0197701065</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: David Chang, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>867250.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>867250.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Allogene Therapeutics, Inc.</issuerName>
    <cusip>019770106</cusip>
    <isin>US0197701065</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>867250.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>867250.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Allogene Therapeutics, Inc.</issuerName>
    <cusip>019770106</cusip>
    <isin>US0197701065</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>867250.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>867250.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To elect two Class II directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified: David Mott</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>441923.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>441923.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To elect two Class II directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified: Michael Raab</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>441923.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>441923.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (&quot;Say-on-Pay&quot;);</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>441923.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>441923.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To ratify the selection, by the Audit and Compliance Committee of our Board of Directors, of Ernst &amp; Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>441923.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>441923.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To approve the Amendment to the Amended and Restated 2014 Equity Incentive Award Plan; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>441923.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>441923.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cidara Therapeutics, Inc.</issuerName>
    <cusip>171757206</cusip>
    <isin>US1717572069</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Jeffrey Stein, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>36762.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>36762.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cidara Therapeutics, Inc.</issuerName>
    <cusip>171757206</cusip>
    <isin>US1717572069</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Bonnie Bassler, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>36762.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>36762.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cidara Therapeutics, Inc.</issuerName>
    <cusip>171757206</cusip>
    <isin>US1717572069</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Ryan Spencer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>36762.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>36762.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cidara Therapeutics, Inc.</issuerName>
    <cusip>171757206</cusip>
    <isin>US1717572069</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the total number of authorized shares of Common Stock from 50,000,000 shares to 100,000,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>36762.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>36762.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cidara Therapeutics, Inc.</issuerName>
    <cusip>171757206</cusip>
    <isin>US1717572069</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Approval of an amendment to the Company's 2024 Equity Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>36762.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>36762.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cidara Therapeutics, Inc.</issuerName>
    <cusip>171757206</cusip>
    <isin>US1717572069</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP by the Audit Committee of the Board to serve as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>36762.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>36762.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cidara Therapeutics, Inc.</issuerName>
    <cusip>171757206</cusip>
    <isin>US1717572069</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>36762.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>36762.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Goran Ando, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Jay S. Duker, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Nancy Lurker</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: John B. Landis, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Wendy DiCicco</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Karen Zaderej</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Stuart Duty</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Fred Hassan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Directors: Reginald Sanders, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To approve Amendment No. 2 to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 2,900,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>EyePoint Pharmaceuticals, Inc.</issuerName>
    <cusip>30233G209</cusip>
    <isin>US30233G2093</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>218703.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>218703.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Vijaya Gadde</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35424.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35424.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Roberto Mignone</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35424.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35424.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Myrtle Potter</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35424.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35424.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of Class I Directors: Musa Tariq</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35424.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>35424.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35424.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35424.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35424.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35424.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immatics N.V.</issuerName>
    <cusip>N44445109</cusip>
    <isin>NL0015285941</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Adopt Financial Statements and Statutory Reports</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>309867.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>309867.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immatics N.V.</issuerName>
    <cusip>N44445109</cusip>
    <isin>NL0015285941</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Approve Discharge of Directors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>309867.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>309867.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immatics N.V.</issuerName>
    <cusip>N44445109</cusip>
    <isin>NL0015285941</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Reelect P.A. Chambre as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>309867.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>309867.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immatics N.V.</issuerName>
    <cusip>N44445109</cusip>
    <isin>NL0015285941</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Reelect H.L. Mason as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>309867.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>309867.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immatics N.V.</issuerName>
    <cusip>N44445109</cusip>
    <isin>NL0015285941</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Elect A.S. Reicin as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>309867.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>309867.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immatics N.V.</issuerName>
    <cusip>N44445109</cusip>
    <isin>NL0015285941</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Authorize Repurchase of Ordinary Shares or Depositary Receipts</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>309867.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>309867.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immatics N.V.</issuerName>
    <cusip>N44445109</cusip>
    <isin>NL0015285941</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Approve 2025 Stock Option and Incentive Plan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>309867.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>309867.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Immatics N.V.</issuerName>
    <cusip>N44445109</cusip>
    <isin>NL0015285941</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Ratify PricewaterhouseCoopers Accountants N.V. as Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>309867.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>309867.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nuvalent, Inc.</issuerName>
    <cusip>670703107</cusip>
    <isin>US6707031075</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of the following nominees as Class I directors: Grant Bogle</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33821.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>33821.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nuvalent, Inc.</issuerName>
    <cusip>670703107</cusip>
    <isin>US6707031075</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of the following nominees as Class I directors: James R. Porter, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33821.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>33821.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nuvalent, Inc.</issuerName>
    <cusip>670703107</cusip>
    <isin>US6707031075</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>Election of the following nominees as Class I directors: Anna Protopapas</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33821.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>33821.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nuvalent, Inc.</issuerName>
    <cusip>670703107</cusip>
    <isin>US6707031075</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation paid to our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33821.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>33821.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nuvalent, Inc.</issuerName>
    <cusip>670703107</cusip>
    <isin>US6707031075</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33821.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>33821.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>The election of Class I directors named in the proxy statement: Santhosh Palani, Ph.D., CFA</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>286408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>286408.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>The election of Class I directors named in the proxy statement: Darren Cline</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>286408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>286408.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>The election of Class I directors named in the proxy statement: Rachel Humphrey, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>286408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>286408.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/18/2025</meetingDate>
    <voteDescription>The ratification of the appointment of Ernst &amp; Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>286408.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>286408.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To re-appoint as a director Arjun Goyal, M.D., M.Phil., M.B.A., who retires by rotation in accordance with the Company's articles of association.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To re-appoint as a director Samarth Kulkarni, Ph.D., who retires by rotation in accordance with the Company's articles of association.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To re-appoint KPMG LLP, a United Kingdom entity, as UK statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company's annual accounts and reports are laid before the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company's independent registered public accounting firm, for the financial year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To authorize the Audit Committee to determine the Company's auditors' remuneration for the financial year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To receive and adopt our UK statutory annual accounts and reports for the financial year ended December 31, 2024 and to note that the Company's directors do not recommend the payment of any dividend for the financial year ended December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To receive and approve, on an advisory basis, the Company's U.K. statutory directors' remuneration report for the financial year ended December 31, 2024, which is set forth as Annex A to the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To receive and approve the Directors' Remuneration Policy as set out in the Company's UK statutory directors' remuneration report for the financial year ended December 31, 2024, which is set forth as Annex A to the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>To generally and unconditionally authorise the directors of the Company or any duly authorised committee of the directors, in accordance with section 551 of the UK Companies Act 2006 (the &quot;Companies Act&quot;), to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds133,184.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Centessa Pharmaceuticals Plc</issuerName>
    <cusip>152309100</cusip>
    <isin>US1523091007</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>Subject to the passing of Resolution 9, to empower the Board of Directors to allot equity securities for cash, under section 570 of the Companies Act as if section 561(1) of the Companies Act did not apply to such allotment up to a maximum aggregate nominal amount of pounds133,184.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>119389.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>119389.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: Rachel K. King</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: John W. Shiver, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: Charles W. Newton</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>The approval, on an advisory basis, of the compensation paid of our Named Executive Officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/20/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Structure Therapeutics Inc.</issuerName>
    <cusip>86366E106</cusip>
    <isin>US86366E1064</isin>
    <meetingDate>06/23/2025</meetingDate>
    <voteDescription>Election of the nominees for Class II director named below to hold office until the 2028 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Eric Dobmeier</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>78960.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>78960.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Structure Therapeutics Inc.</issuerName>
    <cusip>86366E106</cusip>
    <isin>US86366E1064</isin>
    <meetingDate>06/23/2025</meetingDate>
    <voteDescription>Election of the nominees for Class II director named below to hold office until the 2028 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Joanne Waldstreicher, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>78960.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>78960.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Structure Therapeutics Inc.</issuerName>
    <cusip>86366E106</cusip>
    <isin>US86366E1064</isin>
    <meetingDate>06/23/2025</meetingDate>
    <voteDescription>To ratify the appointment by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>78960.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>78960.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Structure Therapeutics Inc.</issuerName>
    <cusip>86366E106</cusip>
    <isin>US86366E1064</isin>
    <meetingDate>06/23/2025</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>78960.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>78960.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Structure Therapeutics Inc.</issuerName>
    <cusip>86366E106</cusip>
    <isin>US86366E1064</isin>
    <meetingDate>06/23/2025</meetingDate>
    <voteDescription>To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>78960.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>78960.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IDEAYA Biosciences, Inc.</issuerName>
    <cusip>45166A102</cusip>
    <isin>US45166A1025</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>To elect two Class III directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Jeffery L. Stein. Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>154726.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>154726.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IDEAYA Biosciences, Inc.</issuerName>
    <cusip>45166A102</cusip>
    <isin>US45166A1025</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>To elect two Class III directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Scott W. Morrison</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>154726.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>154726.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IDEAYA Biosciences, Inc.</issuerName>
    <cusip>45166A102</cusip>
    <isin>US45166A1025</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>154726.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>154726.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IDEAYA Biosciences, Inc.</issuerName>
    <cusip>45166A102</cusip>
    <isin>US45166A1025</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>154726.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>154726.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Jennifer Good</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27281.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27281.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Edward T. Mathers</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27281.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>27281.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27281.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27281.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27281.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27281.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (the &quot;Officer Exculpation Proposal&quot;).</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27281.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27281.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rhythm Pharmaceuticals, Inc.</issuerName>
    <cusip>76243J105</cusip>
    <isin>US76243J1051</isin>
    <meetingDate>06/24/2025</meetingDate>
    <voteDescription>Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27281.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27281.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARS Pharmaceuticals, Inc.</issuerName>
    <cusip>82835W108</cusip>
    <isin>US82835W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Richard Lowenthal</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216583.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>216583.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARS Pharmaceuticals, Inc.</issuerName>
    <cusip>82835W108</cusip>
    <isin>US82835W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Peter Kolchinsky</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216583.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>216583.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARS Pharmaceuticals, Inc.</issuerName>
    <cusip>82835W108</cusip>
    <isin>US82835W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Brenton L. Saunders</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216583.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>216583.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARS Pharmaceuticals, Inc.</issuerName>
    <cusip>82835W108</cusip>
    <isin>US82835W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Peter A. Thompson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216583.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>216583.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARS Pharmaceuticals, Inc.</issuerName>
    <cusip>82835W108</cusip>
    <isin>US82835W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>216583.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>216583.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Inozyme Pharma, Inc.</issuerName>
    <cusip>45790W108</cusip>
    <isin>US45790W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>The election of three Class II directors each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Sarah Bhagat</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>326758.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>326758.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Inozyme Pharma, Inc.</issuerName>
    <cusip>45790W108</cusip>
    <isin>US45790W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>The election of three Class II directors each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Reinaldo Diaz</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>326758.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>326758.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Inozyme Pharma, Inc.</issuerName>
    <cusip>45790W108</cusip>
    <isin>US45790W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>The election of three Class II directors each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Erik Harris</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>326758.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>326758.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Inozyme Pharma, Inc.</issuerName>
    <cusip>45790W108</cusip>
    <isin>US45790W1080</isin>
    <meetingDate>06/25/2025</meetingDate>
    <voteDescription>The ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>326758.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>326758.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>Election Class III Directors, nominated by our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Katina Dorton</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>228320.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>228320.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>Election Class III Directors, nominated by our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Robert J. Gould</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>228320.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>228320.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>Election Class III Directors, nominated by our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders: Kate Haviland</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>228320.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>228320.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>A non-binding advisory vote on executive compensation;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>228320.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>228320.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>A non-binding advisory vote on the frequency of future executive compensation advisory votes; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>228320.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>228320.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>228320.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>228320.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Jeffrey Chodakewitz, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45644.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>45644.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Merit Cudkowicz, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45644.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45644.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45644.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45644.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/26/2025</meetingDate>
    <voteDescription>To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45644.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>45644.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>TScan Therapeutics, Inc.</issuerName>
    <cusip>89854M101</cusip>
    <isin>US89854M1018</isin>
    <meetingDate>06/30/2025</meetingDate>
    <voteDescription>To elect three Class I directors to the Company's Board of Directors: Stephen Biggar</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>393440.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>393440.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>TScan Therapeutics, Inc.</issuerName>
    <cusip>89854M101</cusip>
    <isin>US89854M1018</isin>
    <meetingDate>06/30/2025</meetingDate>
    <voteDescription>To elect three Class I directors to the Company's Board of Directors: Gavin MacBeath</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>393440.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>393440.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>TScan Therapeutics, Inc.</issuerName>
    <cusip>89854M101</cusip>
    <isin>US89854M1018</isin>
    <meetingDate>06/30/2025</meetingDate>
    <voteDescription>To elect three Class I directors to the Company's Board of Directors: Garry Nicholson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>393440.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>393440.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>TScan Therapeutics, Inc.</issuerName>
    <cusip>89854M101</cusip>
    <isin>US89854M1018</isin>
    <meetingDate>06/30/2025</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>393440.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>393440.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
</proxyVoteTable>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
